

CITATION REPORT

List of articles citing

Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study

DOI: 10.1016/j.jacc.2012.05.004

Journal of the American College of Cardiology, 2012, 60, 768-74.

Source: <https://exaly.com/paper-pdf/53144576/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
115	Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. 2013 , 15, 475-83		42
114	Pharmacotherapy of Pulmonary Hypertension. <i>Handbook of Experimental Pharmacology</i> , 2013 ,	3.2	2
113	An update on medical therapy for pulmonary arterial hypertension. 2013 , 15, 614-22		17
112	Daily dosing of PDE5 inhibitors: where does it fit in?. 2013 , 14, 269-78		5
111	Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. 2013 , 34, 811-24		4
110	Management of pulmonary arterial hypertension. 2013 , 19, 44-50		7
109	Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. 2013 , 7, 39-49		13
108	BIOMECHANICAL APPROACH TO THE CLINICAL TREATMENT OF PULMONARY ARTERIAL HYPERTENSION. 2013 , 13, 1340005		3
107	Current world literature. 2013 , 19, 65-73		
106	Phosphodiesterase inhibition in the treatment of autoimmune and inflammatory diseases: current status and potential. 2014 , 19		5
105	Tadalafil prevents acute heart failure with reduced ejection fraction in mice. 2014 , 28, 493-500		18
104	Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension. 2014 , 4, 45-52		3
103	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. 2014 , 2014, 257-90		10
102	Pulmonary hypertension and breathlessness: is it a combination we can ignore?. 2014 , 44, 114-23		4
101	Pulmonary arterial hypertension related to connective tissue disease: a review. 2014 , 40, 103-24		26
100	[Pulmonary hypertension--diagnostic and current concepts]. 2014 , 156, 49-52; quiz 53		
99	Current and advancing treatments for pulmonary arterial hypertension in childhood. 2014 , 8, 615-28		2

98	Upfront triple therapy for pulmonary arterial hypertension: is three a crowd or critical mass?. 2014 , 43, 1556-9	3
97	Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. 2014 , 30, 1233-40	11
96	Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. 2014 , 13, 295-305	15
95	Clinical and molecular genetics of the phosphodiesterases (PDEs). 2014 , 35, 195-233	157
94	Crystal Structure and Desolvation Behaviour of the Tadalafil Monosolvates with Acetone and Methyl Ethyl Ketone. 2015 , 104, 3782-3788	6
93	Clinical Worsening as Composite Study End Point in Pediatric Pulmonary Arterial Hypertension. 2015 , 148, 655-666	22
92	Pulmonary artery ablation to treat pulmonary arterial hypertension: a case report. 2015 , 9, 284	4
91	Central Nervous System and Pulmonary Complications of End-Stage Liver Disease. 2015 , 2107-2128	
90	Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. 2015 , 10, 99-109	19
89	[Medical treatment of pulmonary hypertension: what's new?]. 2015 , 56, 573-82	
88	Pulmonary Arterial Hypertension. 2015 , 313-332	1
87	Medical Therapies for the Treatment of Pulmonary Arterial Hypertension: How Do We Choose?. 2015 , 17, 56	5
86	The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. 2015 , 47, 144-50	29
85	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). 2015 , 45, 1303-13	131
84	Treatment of pulmonary arterial hypertension in children. 2015 , 12, 244-54	44
83	Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD. 2015 , 32, 24-8	2
82	Use of outcome measures in pulmonary hypertension clinical trials. 2015 , 170, 419-29.e3	12
81	Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. 2015 , 193, 105-12	18

80	Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. 2015 , 21, 30-8	121
79	Arterial Disorders. 2015 ,	1
78	Building the case for novel clinical trials in pulmonary arterial hypertension. 2015 , 8, 114-23	14
77	New pharmacotherapy options for pulmonary arterial hypertension. 2015 , 16, 2113-31	17
76	Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. 2015 , 87, 12112-20	18
75	Current treatment approaches to pulmonary arterial hypertension. 2015 , 31, 460-77	24
74	Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets. 2015 , 21, e25-50	87
73	A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy. 2016 , 5,	12
72	Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan. 2016 , 27, 66-70	7
71	Update on pulmonary arterial hypertension pharmacotherapy. 2016 , 128, 460-73	14
70	COPD-associated pulmonary hypertension: clinical implications and current methods for treatment. 2016 , 10, 755-66	4
69	Cetuximab activity in dysplastic lesions of the upper aerodigestive tract. 2016 , 53, 60-6	7
68	Current and future direction in the management of scleroderma. 2016 , 308, 461-71	3
67	Decreased circulating thrombomodulin is improved by tadalafil therapy in hypoxemic patients with advanced pulmonary arterial hypertension. 2016 , 146, 15-19	5
66	You're the Flight Surgeon. 2016 , 87, 833-5	
65	Tadalafil reduces airway hyperactivity and protects against lung and respiratory airways dysfunction in a rat model of silicosis. 2016 , 40, 530-541	23
64	Sklerodermie – mehr als eine Hauterkrankung. 2016 , 32, 44-51	1
63	Global research trends in the medical therapy of pulmonary arterial hypertension 2000-2014. 2016 , 39, 21-7	2

62 Sklerodermie [mehr als eine Hauterkrankung. **2016**, 19, 27-34

61 Lung Circulation. **2016**, 6, 897-943

49

60 Upfront combination therapy: does the AMBITION study herald a new era in the treatment of pulmonary arterial hypertension?. **2016**, 71, 107-9

5

59 The molecular targets of approved treatments for pulmonary arterial hypertension. **2016**, 71, 73-83

87

58 Biochemical and behavioral effects of PDE10A inhibitors: Relationship to target site occupancy. **2016**, 102, 121-35

17

57 Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. **2017**, 151, 468-480

57

56 Targeting the NO-sGC-cGMP Pathway in Pulmonary Arterial Hypertension. **2017**, 139-151

1

55 Safety and effectiveness of tadalafil in patients with pulmonary arterial hypertension: Japanese post-marketing surveillance data. **2017**, 33, 963-971

2

54 Tadalafil in idiopathic or heritable pulmonary arterial hypertension (PAH) compared to PAH associated with connective tissue disease. **2017**, 235, 67-72

9

53 Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia. **2017**, 106, 153-159

3

52 Effect of phosphodiesterase-5 inhibition with Tadalafil on Systolic Right Ventricular size and function - A multi-center, double-blind, randomized, placebo-controlled clinical trial - SERVE trial - Rationale and design. **2017**, 243, 354-359

7

51 Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro. **2017**, 810, 44-50

14

50 Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. **2017**, 8, 47-64

19

49 Diagnosis and Treatment of Pulmonary Hypertension. **2017**,

0

48 Cardiac complications of systemic sclerosis and management: recent progress. **2017**, 29, 574-584

15

47 A review of therapeutic agents for the management of pulmonary arterial hypertension. **2017**, 11, 46-63

8

46 The impact of delayed treatment on 6-minute walk distance test in patients with pulmonary arterial hypertension: A meta-analysis. **2018**, 254, 299-301

8

45 Pulmonary hypertension in patients with interstitial lung disease. **2018**, 50, 38-46

13

44	Pulmonary vasodilation by phosphodiesterase 5 inhibition is enhanced and nitric oxide independent in early pulmonary hypertension after myocardial infarction. 2018 , 314, H170-H179	7
43	OBSOLETE: Pulmonary Hypertension. 2018,	
42	Chronic Right Heart Failure: Expanding Prevalence and Challenges in Outpatient Management. 2018 , 14, 413-423	3
41	Pulmonary Hypertension. 2018, 204-222	
40	Pulmonary Arterial Hypertension: Pathophysiology and Treatment. 2018 , 6,	50
39	Pulmonary Arterial Hypertension and Therapeutic Interventions. 2019 , 28, 80-92	3
38	Clinical efficacy of tadalafil compared to sildenafil in treatment of moderate to severe canine pulmonary hypertension: a pilot study. 2019 , 24, 7-19	4
37	Phosphodiesterase 5 inhibitors for pulmonary hypertension. 2019 , 1, CD012621	32
36	Pulmonary Hypertension and Pregnancy. 2019 , 134, 974-987	15
35	Pulmonary Arterial Hypertension: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions. 2020 , 59, 932-943	6
34	Follow-Up Functional Class and 6-Minute Walk Distance Identify Long-Term Survival in Pulmonary Arterial Hypertension. 2020 , 198, 933-938	4
33	Clinical trial design in phase 2 and 3 trials for pulmonary hypertension. 2020 , 10, 2045894020941491	1
32	An update on the diagnosis and treatment of pediatric pulmonary hypertension. 2020 , 21, 1253-1268	1
31	Riociguat: Clinical research and evolving role in therapy. 2021 , 87, 2645-2662	7
30	Novel Insights Regarding Nitric Oxide and Cardiovascular Diseases. 2021 , 72, 411-425	7
29	Palliative Care in Pulmonary Arterial Hypertension. 2021, 255-279	
28	Pathophysiology and Pharmacotherapy of Adult Congenital Heart Disease. 2015 , 1269-1291	1
27	Contemporary Pharmacotherapies Involving Nitric Oxide, Prostacyclin, and Endothelin Receptor Signaling Pathways. 2016 , 257-270	1

26	Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction. <i>Handbook of Experimental Pharmacology</i> , 2013 , 218, 315-49	3.2	10
25	[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. 2015 , 85, 215-24		6
24	Pulmonary arterial hypertension specific therapy: The old and the new. 2020 , 214, 107576		16
23	Pulmonary Artery Denervation as an Innovative Treatment for Pulmonary Hypertension With and Without Heart Failure. 2021 , 29, 89-95		0
22	Tadalafil-loaded PLGA microspheres for pulmonary administration: preparation and evaluation. 55,		3
21	The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets. 2020 , 27, 7168-7188		10
20	Current and emerging therapeutic approaches to pulmonary hypertension. 2020 , 21, 163-179		20
19	Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo. 2013 , 9, 269-76		54
18	Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety. 2021 , 1		1
17	Diagnosis and Treatment of Pulmonary Arterial Hypertension. 2014 , 1-33		
16	Nitric Oxide Therapeutics in Pulmonary Vascular Disease. <i>Advances in Pulmonary Hypertension</i> , 2014 , 13, 134-137	0.5	
15	Pathophysiology and Treatment of Pulmonary Arterial Hypertension. 2015 , 949-974		
14	Diagnosis and Treatment of Pulmonary Arterial Hypertension. 2015 , 4105-4133		
13	The Real World of Medical Treatment of Pulmonary Arterial Hypertension—Small Evidence, but Heavy Cornerstone— <i>Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery</i> , 2015 , 31, 157-183	0	
12	Whatever Happened to Oral Monotherapy?. <i>Advances in Pulmonary Hypertension</i> , 2017 , 15, 190-192	0.5	
11	Right Heart Failure. 2017 , 161-173		
10	Antihypertonika. 2017 , 335-351		
9	Antihypertonika. 2018 , 385-400		

8	Phosphodiesterase-5 inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2013 , 218, 229-55	3.2	2
7	Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway. <i>Frontiers in Pharmacology</i> , 2021 , 12, 767002	5.6	4
6	A Semi-Automated Term Harmonization Pipeline Applied to Pulmonary Arterial Hypertension Clinical Trials. <i>Methods of Information in Medicine</i> , 2021 ,	1.5	
5	Pulmonary Hypertension. 2021 ,		
4	Safety and Tolerability of Combination Therapy with Ambrisentan and Tadalafil for the Treatment of Pulmonary Arterial Hypertension in Children: Real-World Experience.. <i>Pediatric Pulmonology</i> , 2021 ,	3.5	1
3	Design, synthesis, and biological evaluation of carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects.. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022 , 128663	2.9	2
2	Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial Hypertension.. <i>International Journal of Pharmaceutics</i> , 2022 , 621, 121792	6.5	1
1	Recent Advances in the Treatment of Pulmonary Arterial Hypertension. 2022 , 15, 1277		3